Brokerages Set Evotec AG (NASDAQ:EVO) Target Price at $7.00

Evotec AG (NASDAQ:EVO) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of brokerages have commented on EVO. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Berenberg Bank assumed coverage on Evotec in a report on Tuesday, February 3rd. They issued a “buy” rating on the stock.

Evotec Trading Up 0.3%

EVO stock opened at $3.53 on Tuesday. The company has a 50 day moving average of $3.34 and a two-hundred day moving average of $3.55. Evotec has a 12-month low of $2.84 and a 12-month high of $4.80. The company has a current ratio of 2.12, a quick ratio of 2.03 and a debt-to-equity ratio of 0.48.

Institutional Trading of Evotec

Several hedge funds have recently added to or reduced their stakes in EVO. BNP Paribas Financial Markets lifted its holdings in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares in the last quarter. Bank of America Corp DE raised its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. Valeo Financial Advisors LLC acquired a new position in shares of Evotec in the second quarter valued at approximately $43,000. Thrivent Financial for Lutherans bought a new stake in shares of Evotec during the third quarter worth $53,000. Finally, XTX Topco Ltd acquired a new stake in shares of Evotec during the second quarter worth $66,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.